61 pipeline updates for 42 companies from May 7 and 8

May 09, 2015 1 Comment by

Latest updates to the Company Pipeline Database for May 7 and 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACHN 9.43 ACH-3422 in combination with ACH-3102 HCV Hepatitis C – treatment durations of 6, 8 and 12 weeks Phase 2 Phase 2 to be initiated 2Q 2015. SVR4 results are expected […]

Daily News Read more

Latest calendar updates for AEZS GALE NEOT

Apr 15, 2015 No Comments by

Latest updates to the Company Pipeline Database. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AEZS 0.58 Macimorelin Acetate – Macrilen Adult Growth Deficiency CRL CRL Nov 5 2014. Announced mid-April 2015 plans to initiate a Phase 3 trial GALE 1.45 NeuVax (E75) – PRESENT Cancer – low-to-intermediate HER2+ breast […]

Daily News Read more

Latest biotech updates for week ended March 20

Mar 22, 2015 No Comments by

Latest updates to the Company Pipeline Database for the week ending March 20. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ACRX 4.15 ARX-04 Moderate-to-severe acute pain Phase 3 Phase 3 trial initiated March 2015. Data due 4Q 2015 3/22/2015 ANTH 4.34 Blisibimod Lupus Phase 3 Missed primary endpoints […]

Daily News Read more

Upcoming data for CUR KBIO NKTR. AVNR approval delay likely. DVAX reverse split + AEZS RMTI GNCA HRTX IMMU TLOG OPK DSCO ANAC IMMU HPTX SPPI RPTP CMRX VSAR

Nov 08, 2014 No Comments

Neuralstem, Inc. (NYSE MKT: CUR) announced that the Phase 2 data lock of NSI-566 spinal cord-derived stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS) is scheduled to conclude in late January 2015 at which time the company anticipates providing its Phase 2 ALS results. The company also noted that a Phase 2 trial of NSI-189 for […]

Read more

MDCO and NVS Adcom dates set. AEZS raising more cash. Approvals for BMY AZN GSK + updates for MSTX ALKS

Jan 09, 2014 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.46) announced that it has commenced another underwritten public offering of common shares and warrants, their third offering in just over five months. GW Pharmaceuticals plc (Nasdaq: GWPH $38.06) announced the pricing of its follow-on offering of American Depositary Shares, or ADSs, on the NASDAQ Global Market. GW will issue 2,441,110 ADSs […]

Read more

AEZS PDUFA date set. NBIX meets endpoint. PSTI Ph 1/2 PLX-PAD next week + RCPT GNBT GEVA

Jan 07, 2014 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS)  announced that the FDA has assigned a PDUFA date of November 5, 2014 for Macimorelin Acetate in patients with Adult Growth Hormone Deficiency (AGHD). Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced that they met the primary endpoint in their Phase 2b Kinect 2 trial of NBI-98854 in patients with tardive dyskinesia. They intend to submit […]

Read more

Offering news for AEZS APPA CSII NWBO +CYTR FOLD news

Nov 21, 2013 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.05) priced their public offering of 13.1 million units, with each unit consisting of one common share and one whole warrant to purchase one common share, at a purchase price of US$1.15 per unit. Net proceeds are expected to be approximately $13.7 million. CytRx Corporation (NASDAQ: CYTR $2.15) announced initiation of […]

Read more

AEZS file NDA. IMGN fail Phase 2 trial. ECYT decision due Dec-Jan. ADHD data due Dec. KERX positive data + updates for STEM SGEN PTLA ISIS INSM ZGNX ITMN

Nov 06, 2013 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.39) announced that it has submitted a NDA for AEZS-130 for adult growth hormone deficiency (“AGHD”). ImmunoGen, Inc. (Nasdaq: IMGN $13.41) announced that it will discontinue their Phase 2 trail of IMGN901 for SCLC, following the recommendation from the Data Monitoring Committee (DMC) due to a higher rate of infection and […]

Read more

Updates for AEZS AZN BMRN BMY ITMN MRK NBIX QCOR RNN THRX TSRO VRTX

Jul 25, 2013 No Comments

AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) announced that the FDA has a assigned a PDUFA date of Jan. 11, 2014 for the resubmission of dapagliflozin for the treatment of adults with type 2 diabetes. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced a pipeline update noting that topline data from the Phase 2b Kinect of NBI-98854 against placebo, in tardive dyskinesia […]

Read more

AEZS ATM agreement. AMAG – Rienso recall. ACRX NDA due 3Q + IRWD NPSP BIIB GILD

May 21, 2013 No Comments

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced the pricing of an underwritten public offering of 10,500,000 shares at a price of $13.00 per share for gross proceeds of $136.5 million. Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) announced that it has entered into an “At Market” Issuance (“ATM”) Sales Agreement, with MLV & Co. LLC (“MLV”), where it may, from […]

Read more

Pipeline updates for ACHN BCRX BLRX CLVS RIGL INSM TRGT CBST INFI AEZS SCMP SGEN FURX EXEL FLML TSRX KERX ZIOP ISIS

May 08, 2013 No Comments

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) provided an update noting that interim RVR results from its Phase 2 ACH-3102 trials for the treatment of genotype 1 HCV are due in 3Q 2013 (-007 trial), followed by SVR results during 4Q 2013. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it plans to initiate a Phase 2 trial of BCX4161 in patients with hereditary angioedema, later in 2013 […]

Read more